Tcid50 Measurement
Tcid50 Measurement - Related Videos
08:01
A Streamlined, Label-Free Real-Time 50% Tissue Culture Infectious Dose (TCID50) Assay using Impedance for Automated Viral Titer Quantification
0 Views •
2026
The TCID50 assay reported here leverages label-free real-time impedance measurements and the system's Virology module to objectively monitor virus-induced cytopathic effects (CPE) in real time. This streamlined assay significantly reduces hands-on time while supporting high-throughput, quantitative kinetic CPE measurements and enabling automated, real-time TCID50 calculations.
04:06
Use of Crystal Violet to Improve Visual Cytopathic Effect-based Reading for Viral Titration using TCID50 Assays
0 Views •
Cited by 9 •
2022
This protocol shows an accurate and objective approach to visualize viral titrations using crystal violet, by comparing it with optical microscopy and immunocytochemical staining.
05:33
A Microneutralization Assay to Measure Neutralizing Antibody Titers in Human Serum
0 Views •
2025
This video demonstrates Microneutralization assays to measure neutralizing antibodies using Madin-Darby Canine Kidney cells overexpressing α2,6-linked sialic acid in human sera. This assay is often used for influenza human...
07:22
Standardized Method for Measuring Collection Efficiency from Wipe-sampling of Trace Explosives
0 Views •
Cited by 7 •
2017
Optimized sampling protocols and the development of new wipe materials can be facilitated by standardized measurements of collection efficiency from wipe-sampling. Our approach for sampling trace explosives uses an automated device to control speed, force, and distance during wipe-sampling followed by extraction of collected explosives.
06:56
Micro/Nano-scale Strain Distribution Measurement from Sampling Moiré Fringes
0 Views •
Cited by 7 •
2017
A sampling moiré technique featuring 2-pixel and multi-pixel sampling methods for high-accuracy strain distribution measurements at the micro/nano-scale is presented here.
FAQs
The measurement reports infectious virus, not the total number of particles present in a preparation. Its result therefore reflects the portion of a viral stock capable of producing the assay-defined infection signal in cultured cells. This distinction matters when investigators compare stocks or interpret infectivity, because particle abundance alone does not provide the same measurement.
A dilution series creates a range of exposure conditions, so some wells may show infection while others do not. Statistical analysis uses the observed infection pattern across those dilutions to identify the dilution associated with the 50% endpoint. This calculation converts well-level assay observations into a reported infectious-virus titer for comparing samples.
Replicate wells allow infection to be scored across multiple cultures exposed to the same dilution rather than relying on a single observation. The resulting pattern supplies the observations needed to locate the 50% endpoint statistically. Replication is therefore part of the measurement design, linking individual well outcomes to an overall titer estimate.
Cytopathic effects provide one visible basis for calling a culture infected, but the assay can also use another signal defined by the experimental design. The important requirement is that the chosen readout distinguishes infection across the inoculated wells. That scored response becomes the input for endpoint estimation rather than a direct count of particles.
Researchers first prepare serial virus dilutions and expose replicate tissue-culture wells to those preparations. The cultures are then incubated under controlled conditions, after which infection is scored using cytopathic effects or another assay-defined signal. Finally, statistical analysis identifies the dilution associated with infection in 50% of inoculated wells.
In neutralization studies, an infectious-virus titer helps establish and compare the amount of virus represented by different preparations. Because the measurement is based on infection of tissue-culture wells, it supplies a functional infectivity value for interpreting experimental results. This value also supports consistent standardization of virus inputs across related experiments.
Pathogen characterization can require more than knowing that viral material is present. By estimating the infectious portion of a preparation, this measurement supplies a functional quantity that can be compared among viral stocks and samples. In immunology and infection research, that information helps standardize experiments and relate findings to infectious-virus input.